ReviewRadiation oncology (London, England)2025
Advancements in the application of MRI radiomics in meningioma.
Review in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Early Prediction of Volumetric Progression in Sellar-Parasellar Meningiomas Using Delta Radiomics on 6-Month MRI Following Gamma Knife Radiosurgery.Diagnostics (Basel, Switzerland) · 2026Article
- Tumor location and morphological MRI features in relation to combined 1p/22q deletion in meningioma.Discover oncology · 2026Article
- MRI radiomic signature predicts peritumoral brain edema resolution following meningioma surgery.Acta neurochirurgica · 2025Article
- Context-specific targeting of focal adhesion kinase in brain tumors: lessons from glioblastoma and neurofibromatosis type 2-mutant meningioma.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meningiomas are among the most common intracranial tumors, and challenges still remain in terms of tumor classification, treatment, and management. With the popularization of artificial intelligence technology, radiomics has been further developed and more extensively applied in the study of meningiomas. This objective and quantitative technique has played an important role in the identification, classification, grading, pathology, treatment, and prognosis of meningiomas, although new problems have also emerged. This review examines the application of magnetic resonance imaging (MRI) techniques in meningioma research. A database search was conducted for articles published between November 2017 and April 2025, with a total of 87 studies included after screening. These studies were summarized in detail, and the risk of bias and the certainty of the evidence were assessed using the Quality Assessment of Diagnostic Accuracy Studies version 2 (QUADAS-2) and radiomics quality scores (RQS). All the studies were retrospective, with most being single-center studies. Contrast-enhanced T1-weighted imaging (T1C) and T2-weighted imaging (T2WI) are the most commonly used MRI sequences. Current research focuses on five topics, namely, differentiation, grade and subtypes, molecular pathology, biological behavior, treatment, and complications, with 14, 32, 14, 12, and 19 studies addressing these topics (some of which are multiple topics). Combined imaging features with clinical or pathological features often outperform traditional clinical models. Most studies show a low to moderate risk of bias. Large, prospective, multicenter studies are needed to validate the performance of radiomic models in diverse patient populations before their clinical implementation can be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.